Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresec...
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
About this item
Full title
Author / Creator
Hezel, A F , Noel, M S , Allen, J N , Abrams, T A , Yurgelun, M , Faris, J E , Goyal, L , Clark, J W , Blaszkowsky, L S , Murphy, J E , Zheng, H , Khorana, A A , Connolly, G C , Hyrien, O , Baran, A , Herr, M , Ng, K , Sheehan, S , Harris, D J , Regan, E , Borger, D R , Iafrate, A J , Fuchs, C , Ryan, D P and Zhu, A X
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
Current data suggest that platinum-based combination therapy is the standard first-line treatment for biliary tract cancer. EGFR inhibition has proven beneficial across a number of gastrointestinal malignancies; and has shown specific advantages among
KRAS
wild-type genetic subtypes of colon cancer. We report the combination of...
Alternative Titles
Full title
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4119993
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4119993
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2014.343
